Lineage Cell Therapeutics, Inc. Common Stock (LCTX) CapEx to Revenue & History | Stock Alarm

Demo Sign up Log In

Lineage Cell Therapeutics, Inc. Common Stock · CapEx to Revenue

LCTX CapEx to Revenue

Current (TTM)0.94%retrievedOct 20, 2026

LCTX CapEx/Revenue (0.00% → 0.94%)

Latest values, visible window

High-resolution chart · PNG

LCTX capex to revenue history

Annual fiscal periods. Dates are reporting period ends; fiscal years can differ from calendar years.

Lineage Cell Therapeutics, Inc. Common Stock CapEx to Revenue — Annual fiscal periods
Period ending	CapEx to Revenue
Dec 31, 2025	3.5862%
Dec 31, 2024	5.948%
Dec 31, 2023	7.5349%
Dec 31, 2022	2.809%
Dec 31, 2021	9.0862%
Dec 31, 2020	8.2794%
Dec 31, 2019	29.77%
Dec 31, 2018	232.1328%
Dec 31, 2017	73.9955%
Dec 31, 2016	112.167%
Dec 31, 2015	210.4972%
Dec 31, 2014	24.8204%
Dec 31, 2013	79.5932%
Dec 31, 2012	23.6764%
Dec 31, 2011	22.0857%
Dec 31, 2010	11.8406%
Dec 31, 2009	3.1829%
Dec 31, 2008	57.1802%
Dec 31, 2007	0.6188%
Dec 31, 2006	0.9177%
Dec 31, 2005	0%
Dec 31, 2004	0%
Dec 31, 2003	0%
Dec 31, 2002	0.9899%
Dec 31, 2001	3.3676%
Dec 31, 2000	63.6326%
Dec 31, 1999	15.5874%
Dec 31, 1998	0%
Jun 30, 1998	100%
Jun 30, 1996	0%
Jun 30, 1995	100%
Jun 30, 1994	0%
Jun 30, 1993	0%
Jun 30, 1992	0%

Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.